• Care needs
• Crohn’s disease
• Scale
• Supportive care

• YKK22128 Nanjing Health Science and Technology Development special fund project plan

• Crohn's and Colitis Foundation

• chromoendoscopy
• colorectal cancer
• inflammatory bowel disease
• risk factors
• surveillance

• Crohn’s disease
• remission
• systematic review
• the Crohn’s disease exclusion diet

• Crohn’s disease
• Effectiveness
• Inflammatory bowel disease
• Monoclonal antibodies
• Safety
• Ulcerative colitis

• Africa South of the Sahara/epidemiology
• Chronic Disease
• Colitis, Ulcerative
• Humans
• Inflammatory Bowel Diseases/diagnosis
• Inflammatory Bowel Diseases/epidemiology
• Inflammatory Bowel Diseases/therapy

Multiple genetic risk factors for Crohn’s disease (CD) have been identified. However, these observations are not consistent across different populations. The protein tyrosine phosphate non-receptor type 2 (PTPN2) gene plays a role in various aspects of host defense including epithelial barrier function, autophagy, and innate and adaptive immune response. Two common polymorphisms in the PTPN2 gene (rs2542151 and rs7234029) have been associated with risk of CD in Western countries.

To evaluate the association of PTPN2 gene polymorphisms with risk of CD in Indian population.

We conducted a prospective case-control study. Patients with CD were recruited, and their clinical and investigation details were noted. Controls were patients without organic gastrointestinal disease or other comorbid illnesses. Two common polymorphisms in the PTPN2 gene (rs2542151 and rs7234029) were assessed. DNA was extracted from peripheral blood samples of cases and controls and target DNA was amplified using specific sets of primers. The amplified fragments were digested with restriction enzymes and the presence of polymorphism was detected by restriction fragment length polymorphism. The frequency of alleles was determined. The frequencies of genotypes and alleles were compared between cases and controls to look for significant differences.

A total of 108 patients with CD (mean age 37.5 ± 12.7 years, females 42.6%) and 100 controls (mean age 39.9 ± 13.5 years, females 37%) were recruited. For the single nucleotide polymorphism (SNP) rs7234029, the overall frequency of G variant genotype (AG or GG) was noted to be significantly lower in the cases compared to controls (35.2% vs 50%, P = 0.05). For the SNP rs2542151, the overall frequency of G variant genotype (GT or GG) was noted to be similar in cases compared to controls (43.6% vs 47%, P = 0.73). There were no significant differences in minor allele (G) frequency for both polymorphisms between the cases and controls. Both the SNPs had no significant association with age of onset of illness, gender, disease location, disease behaviour, perianal disease, or extraintestinal manifestations of CD.

Unlike observation form the West, polymorphisms in the PTPN2 gene (rs7234029 and rs2542151) are not associated with an increased risk of developing CD in Indian patients.

• PTPN2 gene
• Crohn’s disease
• Genetic polymorphism
• Case-control study
• Asia
• Risk factor

• IBD-ENC
• Middle East
• South Asia
• South-East Asia
• inflammatory bowel disease

• Aged
• Asia, Southeastern
• Colitis, Ulcerative/diagnosis
• Colitis, Ulcerative/epidemiology
• Colitis, Ulcerative/therapy
• Crohn Disease/diagnosis
• Crohn Disease/drug therapy
• Crohn Disease/epidemiology
• Cross-Sectional Studies
• Delayed Diagnosis
• Asia, Eastern
• Female
• Humans
• Immunologic Factors
• Incidence
• Inflammatory Bowel Diseases/diagnosis
• Inflammatory Bowel Diseases/epidemiology
• Inflammatory Bowel Diseases/therapy
• Male
• Mesalamine
• Phenotype

• Crohn’s disease
• conflicts of interest
• guidelines
• inflammatory bowel disease
• ulcerative colitis

• Crohn disease
• Inflammatory bowel diseases
• Nutritional status
• Postoperative complications
• Surgery
• Ulcerative colitis

• Aged
• Contraindications, Drug
• Crohn Disease/diagnosis
• Crohn Disease/drug therapy
• Crohn Disease/epidemiology
• Humans
• Infliximab/adverse effects
• Italy/epidemiology
• Physicians
• Tumor Necrosis Factor Inhibitors/adverse effects

• Crohn’s disease
• Fluoride
• Gastrointestinal symptoms
• Ileum
• Microbiome

• Animals
• Firmicutes
• Fluorides/toxicity
• Gastrointestinal Microbiome
• Male
• Mice
• Proteome
• Proteomics
• Rats

• R01 DE013508 NIDCR NIH HHS
• T32 DE007306 NIDCR NIH HHS

• Crohn's disease
• Ulcerative colitis
• Vedolizumab

• Asia
• Crohn disease
• Maintenance
• Remission
• Vedolizumab

• Asia/epidemiology
• Humans
• Inflammatory Bowel Diseases/diagnosis
• Inflammatory Bowel Diseases/epidemiology
• Inflammatory Bowel Diseases/therapy
• Medically Underserved Area
• Resource Allocation

• COVID-19
• Corona virus
• Inflammatory bowel disease
• Pandemic
• SARS-CoV-2

• Betacoronavirus
• COVID-19
• Coronavirus Infections/diagnosis
• Coronavirus Infections/etiology
• Coronavirus Infections/prevention & control
• Coronavirus Infections/therapy
• Global Health
• Humans
• Inflammatory Bowel Diseases/complications
• Inflammatory Bowel Diseases/immunology
• Inflammatory Bowel Diseases/therapy
• Pandemics/prevention & control
• Pneumonia, Viral/diagnosis
• Pneumonia, Viral/etiology
• Pneumonia, Viral/prevention & control
• Pneumonia, Viral/therapy
• Risk Assessment
• Risk Factors
• SARS-CoV-2

• Crohn’s disease
• Meta-analysis
• Systematic review
• Tacrolimus

• Crohn's disease
• adalimumab
• biosimilar
• inflammatory bowel disease
• infliximab
• ulcerative colitis

• Asia/epidemiology
• Benchmarking
• Biological Products/adverse effects
• Biological Products/pharmacokinetics
• Biological Products/therapeutic use
• Clinical Decision-Making
• Colitis, Ulcerative/diagnosis
• Colitis, Ulcerative/drug therapy
• Colitis, Ulcerative/epidemiology
• Colitis, Ulcerative/immunology
• Consensus
• Crohn Disease/diagnosis
• Crohn Disease/drug therapy
• Crohn Disease/epidemiology
• Crohn Disease/immunology
• Delphi Technique
• Humans
• Immunologic Factors/adverse effects
• Immunologic Factors/pharmacokinetics
• Immunologic Factors/therapeutic use
• Patient Selection
• Pharmacogenetics
• Risk Factors
• Treatment Outcome

• 2017 JGH Foundation

• Adalimumab
• Colitis, ulcerative
• Crohn disease
• Inflammatory bowel disease
• Infliximab

We compared the initial medical and surgical management of Crohn's disease (CD) and ulcerative colitis (UC) between the United States and China, with aims to better characterize the global variation in the treatment patterns of inflammatory bowel disease (IBD).

Participants from the United States and China completed a questionnaire on demographic and clinical characteristics, medications (biologics, immunomodulators, aminosalicylates, steroids), and IBD‐related surgical history. Patients diagnosed in 2006 and later were eligible. Analysis was restricted to treatment patterns within 1 year of diagnosis. Multivariable logistic regressions examined differences by country.

We recruited 202 CD (US: 49%, China: 51%) and 133 UC (US: 63%, China: 37%) participants. Median age at survey was 31 years (range: 18–76) and at diagnosis was 28 years (range: 12–70). Biologics were commonly used in the United States for CD (66%) and UC (28%) and less commonly in China for CD (19%) and UC (0%). On regression, US CD participants were more likely to receive biologics (odds ratio [OR] 23.82 [95% confidence interval [CI] 8.98–63.14]), aminosalicylates (OR 4.93 [2.00–12.15]), and steroids (OR 4.36 [1.87–10.16]). US UC participants were more likely to receive immunomodulators (OR 3.45 [1.09–10.90]) and steroids (OR 3.31 [1.55–7.06]). There existed minimal differences regarding undergoing surgery for CD (US: 16%, China: 16%) and UC (US: 5%, China: 2%). A proportion (US: 12%, China: 19%) underwent IBD‐related surgery prior to diagnosis (median: 5 years; range: 1–39).

US, relative to Chinese, participants were more likely to report early biologic use. There were no differences between countries in undergoing early surgery. Evaluating global practice variation is integral to optimizing early pharmacological therapy and timing of surgery for patients with IBD.

• Crohn's disease
• biologics
• inflammatory bowel disease
• inflammatory bowel disease (IBD)–related surgery
• ulcerative colitis

• Health system
• Inflammatory bowel disease
• Quality of care
• Treat to target

• Biologics
• Crohn’s disease
• Mucosal healing
• Target

• Adrenal Cortex Hormones/adverse effects
• Adrenal Cortex Hormones/therapeutic use
• Asia/epidemiology
• Azathioprine/adverse effects
• Azathioprine/therapeutic use
• Crohn Disease/drug therapy
• Crohn Disease/epidemiology
• Drug Monitoring
• Humans
• Immunomodulation
• Immunosuppressive Agents/adverse effects
• Immunosuppressive Agents/therapeutic use
• Incidence
• Infliximab/adverse effects
• Infliximab/therapeutic use
• Methotrexate/adverse effects
• Methotrexate/therapeutic use
• Purines/adverse effects
• Purines/therapeutic use
• Remission Induction
• Thalidomide/adverse effects
• Thalidomide/therapeutic use
• Thionucleosides/adverse effects
• Thionucleosides/therapeutic use
• Treatment Outcome
• Tumor Necrosis Factor-alpha/antagonists & inhibitors

• azathioprine
• crohn disease
• dose
• efficacy
• remission

• Adult
• Azathioprine/administration & dosage
• Azathioprine/adverse effects
• Crohn Disease/drug therapy
• Female
• Follow-Up Studies
• Glucocorticoids/therapeutic use
• Humans
• Immunosuppressive Agents/administration & dosage
• Immunosuppressive Agents/adverse effects
• Intention to Treat Analysis
• Male
• Middle Aged
• Prospective Studies
• Remission Induction
• Treatment Outcome

• Crohn's disease
• esophageal diseases
• oral pathology
• stomach diseases
• upper gastrointestinal tract

• Chromoendoscopy
• Colitis screening
• Colitis surveillance
• Colorectal cancer
• Inflammatory bowel disease

Crohn's disease (CD) is a chronic relapsing and remitting inflammatory disease of the gastrointestinal tract. CD is rare in Taiwan and other Asian countries, but its prevalence and incidence have been steadily increasing. A steering committee was established by the Taiwan Society of Inflammatory Bowel Disease to formulate statements on the diagnosis and management of CD taking into account currently available evidence and the expert opinion of the committee. Thorough clinical, endoscopic, and histological assessments are required for accurate diagnosis of CD. Computed tomography and magnetic resonance imaging are complementary to endoscopic evaluation for disease staging and detecting complications. The goals of CD management are to induce and maintain remission, reduce the risk of complications, and improve quality of life. Corticosteroids are the mainstay for inducing re-mission. Immunomodulating and biologic therapies should be used to maintain remission. Patients should be evaluated for hepatitis B virus and tuberculosis infection prior to treatment and receive regular surveillance for cancer. These consensus statements are based on current local evidence with consideration of factors, and could be serve as concise and practical guidelines for supporting clinicians in the management of patients with CD in Taiwan.

• Consensus statements
• Crohn disease
• Disease management
• Inflammatory bowel diseases
• Taiwan

• Crohn's disease
• Guidelines
• Treatment

The increasing number of older patients (age ≥60 years) with inflammatory bowel disease (IBD) highlights the importance of healthcare maintenance in this vulnerable population. Older IBD patients are more susceptible and have higher rates of many disease- and treatment-related adverse effects. Compared to younger IBD patients, older patients are at increased risk for infection, malignancy, bone disease, eye disease, malnutrition and thrombotic complications. Preventive strategies in the elderly differ from those in younger adults and are imperative. Changes to the immune system with aging can decrease the efficacy of vaccinations. Cancer screening guidelines in older IBD patients have to account for unique considerations, such as life expectancy, functional performance status, multimorbidity, financial status, and patient desires. Additionally, providers need to be vigilant in screening for osteoporosis, ocular disease, depression, and adverse events arising from polypharmacy.

• Age
• elderly
• healthcare maintenance
• inflammatory bowel disease

Crohn's disease (CD) is a chronic, progressive, and disabling inflammatory bowel disease (IBD) with an uncertain etiopathogenesis. CD can involve any site of the gastrointestinal tract from the mouth to the anus, and is associated with serious complications, such as bowel strictures, perforations, and fistula formation. The incidence and prevalence rates of CD in Korea are still lower compared with those in Western countries, but they have been rapidly increasing during the recent decades. Although there are no definitive curative modalities for CD, various medical and surgical therapies have been applied for the treatment of this disease. Concerning CD management, there have been substantial discrepancies among clinicians according to their personal experience and preference. To suggest recommendable approaches to the diverse problems of CD and to minimize the variations in treatment among physicians, guidelines for the management of CD were first published in 2012 by the IBD Study Group of the Korean Association for the Study of Intestinal Diseases. These are the revised guidelines based on updated evidence, accumulated since 2012. These guidelines were developed by using mainly adaptation methods, and encompass induction and maintenance treatment of CD, treatment based on disease location, treatment of CD complications, including stricture and fistula, surgical treatment, and prevention of postoperative recurrence. These are the second Korean guidelines for the management of CD and will be continuously revised as new evidence is collected.

• Crohn disease
• Guideline
• Management

• Abdominal Abscess/diagnostic imaging
• Abdominal Abscess/drug therapy
• Abdominal Abscess/etiology
• Abdominal Abscess/surgery
• Adult
• Aneurysm, False/etiology
• Coinfection/drug therapy
• Crohn Disease/complications
• Drainage
• Fasciitis/etiology
• Humans
• Ileal Diseases/diagnostic imaging
• Ileal Diseases/etiology
• Interdisciplinary Communication
• Intestinal Perforation/diagnostic imaging
• Intestinal Perforation/etiology
• Laparotomy
• Leg/diagnostic imaging
• Male
• Peritonitis/drug therapy
• Peritonitis/etiology
• Peritonitis/microbiology
• Reoperation
• Retroperitoneal Space/diagnostic imaging
• Sepsis/drug therapy
• Sepsis/etiology
• Tomography, X-Ray Computed

• Asia
• Crohn's disease
• Epidemiology
• Genetics
• Phenotype
• Ulcerative colitis

This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).

Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220–450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8–26; patients received 40 mg adalimumab every other week. Serum adalimumab concentration and change from baseline in fecal calprotectin (FC) were measured during the double-blind period. Clinical remission (CDAI <150), response (decrease in CDAI ≥70 points from baseline), and change from baseline in hs-CRP were assessed through week 26. Nonresponder imputation was used for missing categorical data and last observation carried forward for missing hs-CRP/FC values. No formal hypothesis was tested. Adverse events were monitored.

Mean adalimumab serum concentrations during the induction phase were 13.9–18.1 µg/mL (160/80 mg group) and 7.5−9.5 µg/mL (80/40 mg group). During the double-blind period, higher remission/response rates and greater reductions from baseline in hs-CRP and FC were observed with adalimumab 160/80 mg compared to that with 80/40 mg. Adverse event rates were similar among all treatment groups.

Adalimumab serum concentrations in Chinese patients with CD were comparable to those observed previously in Western and Japanese patients. Clinically meaningful remission rates and improvement in inflammatory markers were achieved with both dosing regimens; changes occurred rapidly with adalimumab 160/80 mg induction therapy. No new safety signals were reported.

• Adalimumab
• Anti-tumor necrosis factor
• Crohn disease

• Biomarkers/metabolism
• Chromatography, Liquid/methods
• Crohn Disease/metabolism
• Crohn Disease/pathology
• Diagnosis, Differential
• Female
• Gene Ontology
• Humans
• Intestinal Mucosa/metabolism
• Intestinal Mucosa/pathology
• Male
• Proteomics/methods
• Tandem Mass Spectrometry/methods
• Tuberculosis, Gastrointestinal/metabolism
• Tuberculosis, Gastrointestinal/pathology